Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Herling M, Dearden C, Zaja F, El-Sharkawi D, Ding W, Bellido M, Khot A, Tick L, Jacobsen E, Eyre TA, Roos-Weil D, Kadia T, Lucchini E, Pflug N, Davids MS, Pena G, Mukherjee N, Badawi M, Vizkelety T, Staber PB.
Herling M, et al. Among authors: el sharkawi d.
Blood Adv. 2024 Feb 27;8(4):842-845. doi: 10.1182/bloodadvances.2023012248.
Blood Adv. 2024.
PMID: 38190628
Free PMC article.
Clinical Trial.
No abstract available.